Jubilant Tx is a patient-focused biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology & autoimmune diseases.

Biotechnology

Jubilant Therapeutics

Robert Glassman joined the Board of Directors in February of 2021. Dr. Glassman is the venture partner in public equity for OrbiMed Advisors, with more than 17 years of experience in investment banking, most recently having served as Managing Director and Vice Chairman in the Global Investment Banking Group at [Credit Suisse](/org/credit-suisse) since 2015. Prior to [Credit Suisse](/org/credit-suisse), Dr. Glassman was with Merrill Lynch Global Private Equity where he oversaw a very successful healthcare portfolio. Earlier, he consulted for a wide range of healthcare clients in the U.S. and Europe at [McKinsey & Company](/org/mckinsey-company). Formerly a board-certified hematologist-oncologist, he remains on the faculty of Weill Cornell as a Clinical Assistant Professor of Medicine. Dr. Glassman received his AB magna cum laude from Harvard College and an MD from Harvard Medical School. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, and his fellowship in hematology and oncology at Weill Cornell. He was an investigator at [Rockefeller University](/org/rockefeller-university) in the laboratory of Hidesaburo Hanafusa where he received [Howard Hughes Medical Institute](/org/howard-hughes-medical-institute) and [American Cancer Society](/org/american-cancer-society) awards. He currently serves on the Boards of Taurus Therapeutics, [Umoja Biopharma](/org/umoja-biopharma) and [Pharvaris](/org/pharvaris).

Robert Glassman

Mohd Zainuddin is Director- Biology at Jubilant Therapeutics Inc. Previously, Zain worked on Drug metabolism and pharmacokinetics (DMPK) at Jubilant Biosys Ltd., where he has executed close to 40 Drug discovery projects from various pharma clients. He has in depth understanding on various domains of DMPK and has played a critical role in many successful lead and candidate nominations.

Zain has published nearly 45 peer-reviewed journal articles and holds 6 patents for inventorship in drug discovery and development.

He holds a Ph.D. in medical biochemistry from Aligarh Muslim University, Aligarh, India.

Mohd Zainuddin

Jeremy Barton, M.D. has over 29 years of experience in all phases of oncology drug development in the pharmaceutical industry in Switzerland, UK and currently in the US.

Most recent industry responsibilities have included Chief Medical Officer roles at Biogen Idec, eFFECTOR Therapeutics and Mirati Therapeutics. He was also head of early Oncology Development at Pfizer for 5 years overseeing the transition of all Oncology compounds from research through IND to proof of concept studies.

After obtaining a Masters Degree in Physiology from Oxford University and his M.D. degree at University College Hospital Medical School in London, he trained in Internal Medicine and Clinical Oncology in the United Kingdom and practiced for 11 years in the National Health Service.

Jeremy is Board Certified in Internal Medicine and Clinical Oncology, a Member of the Royal College of Physicians, a Fellow of the Royal College of Radiologists (Clinical Oncology) and a Member of Faculty of Pharmaceutical Medicine.

Jeremy Barton

Founder of Jubilant Bhartia Group, valued at around US $5 Billion and 42,000 employees globally, has a leadership position in diverse sectors like Pharmaceuticals, Contract Research and Development Services, Proprietary Novel Drugs, Life Science Ingredients, Agri Products, Performance Polymers, Food Service (QSR), Food, Auto, Consulting in Aerospace and Oilfield Services.

Member of World Economic Forum’s International Business Council; Community of Chairpersons; Global Health and Healthcare Governors Community; Family Business Community. He was the Co-Chair of the Davos Annual Meeting of the World Economic Forum in 2015.

Hari S Bhartia

Dr. Alland is currently Chief Medical Officer of PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, and a Member of the Board of Directors, Jubilant Therapeutics.

Leila, a pediatric hematologist-oncologist and accomplished physician-scientist, has been working in the biopharmaceutical industry since 2001 to bring novel therapies to patients. Previously, Dr. Alland served as Chief Medical Officer at Affimed, and prior to that she held the same position at Tarveda Therapeutics. Dr. Alland also held leadership positions at AstraZeneca, Bristol-Myers Squibb, Novartis, and Schering-Plough, where she worked on a broad range of oncology products from early to late-stage development and contributed to multiple successful drug approvals.

Earlier in her career, Leila served as Assistant Professor of Pediatrics at Albert Einstein College of Medicine, where she was awarded the James S. McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer and blood disorders. Dr. Alland is on the Board of Directors of Abeona Therapeutics, Inc. and Cytovia Therapeutics, Inc. Leila is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research and serves as a scientific reviewer for the Cancer Prevention and Research Institute of Texas.

Leila obtained her medical degree from New York University School of Medicine, and her B.A. in Biology from the University of Pennsylvania. She completed her residency in Pediatrics at The Children’s Hospital of Philadelphia, and her fellowship in Pediatric Hematology/Oncology at The New York Hospital and Memorial Sloan-Kettering Cancer Center.

Leila Alland

Mr. Chokhany is Group Chief Financial Officer, Jubilant Bhartia Group, and a Member of the Board of Directors, Jubilant Pharmova Limited, and Jubilant Therapeutics.

Arvind has over 25 years of experience with leadership roles in large multinational institutions like Tata’s, Deutsche bank, Standard Chartered and HDFC Bank. In addition, he brings proficiency in strategic business planning, business origination and development, policy advocacy and change management, investments underwriting, portfolio and asset management, finance operations, capital and balance sheet management, mergers & acquisitions, structured debt & equity origination, investor relations and board management.

Previously, Arvind was the CFO for multiple Tata group entities, where he managed the financial, customer and stakeholder governance, joint venture partner selection and agreements, investments underwriting, enhancing the investor ROCE through divestments, finance operations, and risk governance.

Arvind is a merit rank-holder in professional examinations of both, the Institute of Cost and Work Accountants of India (ICWAI), and the Institute of Chartered Accountants of India (ICAI).

Arvind Chokhany

Luca Rastelli is the Chief Scientific officer of Jubilant Therapeutics Inc., a subsidiary of Jubilant Pharmova Limited. Luca brings to Jubilant Therapeutics more than 20 years of oncology drug discovery and development experience, as well as business development experience ranging from startups to large pharmaceutical companies. Most recently, he was CSO at Kleo Pharmaceuticals where he led all aspects of R&D for the company and was instrumental in bringing a CD38 targeting compound based on Kleo novel ARM technology to the clinics for multiple myeloma.

Previously Luca was Vice President, Oncology at BioXcel Therapeutics where he helped bring the company to a successful IPO. He has held multiple preclinical and clinical project leadership positions at Boston Scientifics, CuraGen, Sopherion and EMD Serono (Merck Serono). He led the initial development of c-MET inhibitor TEPMETKO, approved for the treatment of METex14 positive NSCLC patients. Luca was also part of the initial development of the immuno-oncology antibody BAVENCIO, a PDL-1 inhibitor approved for several type of cancers. He received the American Brain Tumor Association's 25th Anniversary Translational grant for his work on Medulloblastoma tumors at the Department of Neuro-Oncology, MD Anderson Cancer Center. He is a named inventor on more than 10 issued patents and holds a Ph.D. in Molecular Biology from the University of Geneva.

Luca Rastelli

Syed Kazmi is President and Chief Executive officer of [Jubilant Therapeutics](/org/jubilant-therapeutics) Inc., a subsidiary of Jubilant Life Sciences Ltd. [Jubilant Therapeutics](/org/jubilant-therapeutics) is a US based innovative biopharmaceutical company developing breakthrough therapies for treating unmet medical need in serious diseases such as cancer.

Previously, Syed worked as the Vice President and Global Head of Oncology Business Development & Licensing at [Novartis](/org/novartis), leading all BD&L efforts for [Novartis](/org/novartis) Oncology including Search & Evaluation, Transactions, Due Diligence and Alliance Management. Prior to [Novartis](/org/novartis), Syed worked as the Executive Director of Business Development at [Amgen](/org/amgen), responsible for corporate mergers and acquisitions, global licensing and strategic collaborations; he also served as the Head of International Business Development.

Prior to joining [Amgen](/org/amgen) in 2012, Syed served as Vice President and Head, Business Development & Strategic Planning, at [Ligand Pharmaceuticals](/org/ligand-pharmaceuticals). Syed also worked for [Johnson & Johnson](/org/johnson-johnson) as Principal Scientist in the R&D organization. Syed has a Ph.D. in Life Sciences (Biochemistry) and an executive MBA.

Syed Kazmi

Ramachandraiah Gosu (Ram) is Director- Protein Chemistry of Jubilant Therapeutics Inc.. Ram brings wealth of experience in protein engineering, macromolecular X-ray Crystallography, Biophysics with special focus on small molecule drug discovery using SBDD and FBDD.

Previously he was heading Structural Biology department of Jubilant Biosys Ltd., Bangalore. He contributed in success of many challenging gene-to-structure projects of collaborators over 14 years and pioneered in establishing biophysical screening platform, SPR (Surface Plasmon Resonance).

Ram has published ~ 11 peer-reviewed journal articles and co-edited a book on "Methods for fragments screening using SPR", published by Springer Nature.

He holds Ph.D in Structural Biology from Molecular Biophysics Unit of Indian Institute of Science, Bangalore, India and gained post-doctoral experience at University of Minnesota, Minneapolis, USA.

Ramachandraiah Gosu

Dhanalakshmi Sivanandhan is Associate Vice President of Biology at Jubilant Therapeutics Inc., a subsidiary of Jubilant Life Sciences Ltd.

Previously, Dhanalakshmi worked as Head of Oncology therapeutic area at Jubilant Biosys Ltd., where she executed close to 25 Oncology discovery projects delivering three pre-clinical candidates and out-licensed one of the in-house projects to a US based Biotech.

Prior to joining Jubilant in 2007, Dhanalakshmi has completed two post-doctoral trainings, at National Cancer Center, Tokyo, Japan and at University of Colorado Health Sciences Center, Denver, USA. She received her Ph.D in Life Sciences (Cancer research) from Jawaharlal Nehru University, New Delhi, India.

Dhanalakshmi Sivanandhan

Sridharan Rajagopal (Raj) is Vice President and Head of Medicinal Chemistry of Jubilant Therapeutics Inc. (JTx), a subsidiary of Jubilant Life Sciences Ltd. Raj brings a wealth of experience in drug discovery, medicinal chemistry and epigenetics to JTx. Prior to joining, he spent 5 years in various positions at Jubilant Biosys as Associate Director, Director and Associate Vice President, where under his leadership the company delivered several LO and preclinical candidates working with various small biotech and Big Pharma.

He also spent 7 years in various positions as Senior Scientist, Chief Research Scientist and Associate Director at Orchid Pharmaceuticals Ltd, India, where he was instrumental in developing a healthy pipeline in Oncology and Inflammation and advanced two candidates into the clinic in cancer and inflammation. He also worked for 2 years at Aurigene Discovery Technologies Ltd, India as Senior Scientist.

Raj has published nearly 25 peer-reviewed journal articles and holds 19 patents in drug discovery and development. He holds an M.S and a PhD from Indian Institute of Science, India and postdoctoral experiences from [University of Miami](/org/university-of-miami), [Miami University](/org/miami-university) and University of Missouri.

Sridharan Rajagopal

William Lambert, Ph.D., is the founder of Module 3 Pharmaceutical Consulting where he provides expert consultation in the Chemistry, Manufacturing, and Controls area for both large and small molecule therapeutics. Prior to Module 3, he was the Vice President of CMC at Omeros Corporation. At AstraZeneca/MedImmune, he led the Innovative Drug Delivery Group. He was Sr. VP of Pharmaceutical Development at [Pacira Pharmaceuticals](/org/pacira-pharmaceuticals). He also held various positions in drug delivery, product development, and manufacture at Eisai Inc., [Pfizer](/org/pfizer), and the Upjohn Company. In the above positions, he contributed to the development and registration efforts of several marketed drugs including Corvert (anti-arrhythmic), Trovan (antibiotic), Halaven (anti-cancer), Exparel (post-surgical pain), Fasenra (benralizumab, asthma), and Omidria (ophthalmic).

Dr. Lambert received his B.S. in Pharmacy from the Univ. of Rhode Island followed by graduate studies in Pharmaceutics at the Univ. of Michigan and Utah. He is a member of the Advisory Boards of J. Pharm. Sci. and the Handbook of Pharmaceutical Excipients, and was previously on boards for the USP Excipient Expert Committee, AFPE, NIPTE, and chair of the Pharm Tech Section of the AAPS.

William Lambert

Dr. Scott is the Founder and Principal of Katovar Consulting , and has worked as an independent consultant for a range of biopharmaceutical and venture capital firms, ranging from start ups and virtual companies to mid-size and large pharma, supporting global regulatory interactions from FIH to marketing authorizations, and beyond.

Dr Scott's last FTE position was on the Regulatory Team of Trius Therapeutics, where she facilitated the US, EU and Canadian marketing applications for their first product Sivextro (tedizolid phosphate), supporting Health Authority meetings (including an Advisory Committee meeting), submissions and responses to Agency queries, while building the regulatory infrastructure for a commercial organization. Her prior roles have been positions of increasing responsibility and scope within regulatory affairs at [Pfizer](/org/pfizer), [Amgen](/org/amgen) and Schering-Plough Research Institute

Dr. Scott received a PhD from [Purdue University](/org/purdue-university) in Pharmacology (specialization neuroscience), followed by a postdoctoral fellowship at the [Mayo Clinic](/org/mayo-clinic) in the emerging field of pharmacogenetics. She also has an MBA in Pharmaceutical/Chemical Studies from Fairleigh-Dickinson University, an MS in Biology from California State University, Long Beach and a BS in Biological Sciences from the [University of California, Irvine](/org/university-of-california-irvine).

Mary Celine Scott

As President of Parallel 33 Consulting, Inc., Ron provides professional scientific and regulatory advice in clinical pharmacology, toxicology, and DMPK in drug development to support the safe and effective use of pharmaceutical products as specified by IND, BLA, and NDA requirements. His principal strengths include directing and managing nonclinical/early clinical development activities supporting development of small molecules, protein conjugates, monoclonal antibodies, cellular therapies, infectious disease and gene therapies in the pharmaceutical industry as an independent consultant.

Ron has over 30 years’ experience in the pharmaceutical and biotech industries with extensive experience in pharmaceutical (small molecule and biotherapeutics) research and development. He received his doctorate in Veterinary Toxicology from [Texas A&M University](/org/texas-a-m-university) and is a Diplomate of the American Board of Toxicology (2003) and Fellow, American College of Clinical Pharmacology (2011). In his most recent role, he was Vice President, Drug Development at [Arena Pharmaceuticals](/org/arena-pharmaceuticals), Inc. (San Diego, CA) and was responsible for drug safety, drug disposition and early clinical development activities supporting metabolic, cardiovascular, CNS and autoimmune therapeutic areas. Prior to joining [Arena Pharmaceuticals](/org/arena-pharmaceuticals), Ron has served in various management roles within the research and development industry, to include Takeda Pharmaceuticals, [Johnson & Johnson](/org/johnson-johnson), Schering-Plough, [Bayer](/org/bayer), and [Ligand Pharmaceuticals](/org/ligand-pharmaceuticals). Ron has supported with teaching at the University of California, San Diego Skaggs School of Pharmacy in an adjunct professor role and has published more than 75 original peer-reviewed publications, conference abstracts and chapters in the areas of pharmacology, drug metabolism, pharmacokinetics, exposure-response modeling, biopharmaceutics, and drug-drug interactions in therapeutic areas of oncology, CNS, inflammation and metabolic research. Ron holds a B.S. in pathobiology from The University of Connecticut (Storrs).

Ron Christopher

Rajeev Mohan is the Senior Director & Head, Program Management at Jubilant Therapeutics Inc., and has 18+ years of diverse pharmaceutical experience encompassing business strategy, portfolio selection, commercial operations, manufacturing and R&D.

Most recently, Rajeev managed consulting engagements in areas of strategic planning, new opportunities evaluation, and commercial operations. Prior to this, Rajeev was part of Vensun Pharma's executive team managing it's organic and inorganic growth, including multiple equity and debt financing rounds. Early on, Rajeev successfully transitioned from a technical to a commercial role at URL Pharma (now Takeda) and Andrx Pharma (now Teva).

Rajeev holds an MBA from [Cornell University](/org/cornell-university), a Doctorate in Chemical Engineering from NYU, and a Bachelors in Chemical Engineering from Osmania University, India.

Rajeev Mohan

Agunan Krishnan is the Associate Director at Jubilant Therapeutics Inc., and with 14+ years of experience in the drug discovery field, is responsible for sales, marketing and business development. He is also responsible for establishing business partnerships and collaborations utilizing his expertise in the drug discovery process and techno-commercial knowledge.

Previously, Agunan worked at Jubilant Biosys, where he started as a research scientist in structural biology and transitioned into market research, strategy and business development. During his tenure he was involved in onboarding business opportunities and the out-licensing of a research program.

He has completed a bachelor’s degree in Veterinary Medicine from Madras Veterinary College, TANUVAS, India and post-graduate studies in Molecular Biology from [Staffordshire University](/org/staffordshire-university), UK.

Agunan Krishnan

Shyam is CFO at Jubilant Therapeutics Inc. that he helped carve out from the parent company Jubilant Life Sciences and set up as a standalone U.S. based biotech venture in 2019. Shyam is also involved in other initiatives at Jubilant such as corporate venture investing, digital and innovation.

Earlier he managed the strategy office at a leading India based conglomerate where he helped scale a new business and managed a successful M&A exit valued at over a billion dollars. Prior to Shyam's industry stints, he spent most of his career as a management consultant at PwC – advising startups and leading global companies in strategy. Shyam has spoken at various conferences and is an active participant in the [World Economic Forum](/org/world-economic-forum) community in addition to authoring over fifty thought leadership publications.

He is a graduate of London School of Economics and State University of New York.

Jubilant Therapeutics

Org chart

Teams

Board of Directors

Leadership Team

CEO and Executive Team

Discover similar companies